Abstract: The present disclosure provides methods of treating an ocular disease or disorder. The methods involve direct administration into the eye of a conjugate comprising a biologically active polypeptide and a biocompatible polymer.

Abstract: The present disclosure provides antibody-drug conjugate structures. The antibody-drug conjugate structures include a branched linker where two or more payloads per branched linker are attached to a polypeptide (e.g., an antibody). In addition, the disclosure also encompasses compounds and methods for production of such conjugates. In addition, the disclosure also encompasses methods of using the conjugates.

Abstract: Provided herein are peptides and peptide conjugates comprising a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. The peptides may be used for blood glucose management and treating conditions such as diabetes, obesity, non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH).

Abstract: The present disclosure provides, in one aspect, bifunctional compounds that can be used to promote or enhance degradation of an extracellular or cell surface protein. In certain embodiments, the extracellular protein mediates a disease and/or disorder in a subject, and treatment or management of the disease and/or disorder requires degradation, removal, and/or reduction in concentration of the protein in the subject. In some embodiments, the disease and/or disorder is a neurological disease and/or disorder. Thus, in certain embodiments, administration of a compound of the disclosure to the subject removes or reduces the amount of the extracellular or cell surface protein in the brain, thus treating, ameliorating, or preventing the disease and/or disorder.

Abstract: Protein conjugates comprising a protein carrier comprising polyethylenimine, a payload that interacts with an intracellular target and a linker are provided. Pharmaceutical composition comprising the protein conjugates as well as methods of using and producing the protein conjugates are also provided.

Abstract: The present disclosure relates generally to antibody-drug conjugates comprising peptide-containing linkers and to methods of using these conjugates as therapeutics and/or diagnostics. Also disclosed herein are peptide-containing scaffolds useful to conjugate with a targeting moiety (e.g., an antibody), a drug, or both to produce the antibody-drug conjugates.

Abstract: The disclosure provides compositions comprising intercellular adhesion molecule 1 (ICAM1) antibody and methods for using the same for therapeutic applications, for example, treating triple negative breast cancer (TNBC) and predicting drug response.

Abstract: Provided herein are antibody drug conjugates of Formula (I): G-R7(I) and pharmaceutically acceptable salts thereof, wherein G is a molecular payload; and R7 is -L-A-B, wherein L is a linking group, A is a conjugating group, and B is an antibody or antibody fragment. Also provided are methods of preparing the antibody-drug conjugates, pharmaceutically acceptable compositions thereof, and methods of their use and treatment. Further provided are precursors to the antibody drug conjugates (e.g., compounds of Formula (III), novel trioxacarcins without an antibody conjugated thereto), pharmaceutical compositions thereof, and methods of their use and treatment.

Abstract: The present disclosure relates to therapies for FOLR1 expressing cancers, such as pediatric acute myeloid leukemia, (e.g., CBF/GLIS acute myeloid leukemia), with antibody conjugates with binding specificity for folate receptor alpha (FOLR1) and its isoforms and homologs. Also provided are methods of using the combinations with antibody conjugates and compositions thereof, such as in therapeutic and palliative methods.

Abstract: Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload inhibits expression or activity of a DMPK allele comprising a disease-associated-repeat. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide or RNAi oligonucleotide.

Abstract: The present invention provides an antibody-drug conjugate specifically binding to B7H3 and a pharmaceutical composition comprising the same. A method for using the antibody-drug conjugate of the present invention and use thereof are also provided herein.

Abstract: An object of the present invention is to provide an anticancer drug capable of treating cancer by finding a target molecule specifically expressed in cancer cells and by specifically acting on the target molecule, and to provide a cancer testing method including a step of measuring the target molecule in a sample. The present invention provides an anticancer drug containing, as an active ingredient thereof, an anti-transmembrane protein 180 (TMEM-180) antibody or an antigen-binding fragment thereof. In addition, the present invention provides a cancer testing method including a step of measuring the amount of TMEM-180 in a sample collected from a subject.

Abstract: Provided is use of an antibody-drug conjugate targeting Her2 in the preparation of a medicine for treating breast cancer patients with liver metastasis or breast cancer patients without lung metastasis. Compared with a control drug group (lapatinib+capecitabine), the application of the antibody-drug conjugate provided in the treatment of breast cancer patients with liver metastasis and in the treatment of breast cancer patients without lung metastasis can significantly improve the survival time of the patients.

Abstract: An antibody-drug conjugate represented by formula (I): (where Ab is an antibody, X is a group represented by formula (X-1), formula (X-2) or formula (X-3): (where at the left represents the binding site with NH and at the right represents the binding side with D), D is a group represented by formula (D-1) or formula (D-2): (where represents the binding site with X), and n is in the range of about 1 to about 8).

Abstract: Aspects of the invention described herein include a hydrogel prodrug and methods of making a hydrogel prodrug for drug delivery. Also contemplated are methods of treating, inhibiting, ameliorating or inhibiting a disease or disorder. Without being limiting, the methods for treatment can be directed to a cancer, HIV, a virus, pain, a bacterial infection, a neurological disorder, hemorrhaging, multiple sclerosis, diabetes, high blood pressure, Alzheimer's, or inhibiting a fungal growth in a subject in need.

Abstract: The present disclosure relates to a mRNA delivery composition comprising cationic lipid-based liposome. The mRNA delivery composition according to the present disclosure is superb in terms of storage stability and exhibits high intracellular delivery and expression rates in vivo and thus, can enhance the stability and efficiency of mRNA vaccines for cancer therapy or mRNA vaccines for prevention of viral infections.

Abstract: A ferritin protein according to an embodiment of the present disclosure has an outer surface on which a molecule configured to bind to an immune checkpoint molecule. The present invention relates to a protein used with a disease antigen and a use of same. The A ferritin protein is formed via self-assembly of ferritin monomers fused with a disease antigen epitope. The protein exhibits excellent binding affinity to a human transferrin receptor, and thus can provide various kinds of disease antigen epitopes with different lengths to antigen-presenting cells so as to induce an immune response to the corresponding antigen.

Abstract: Described herein are compositions and methods for targeting cancer cells and inducing cell death. In one embodiment, the composition comprises a nanoparticle system comprising a plurality of antibodies that recognize CAR-T cells and a plurality of antibodies that recognize cancer cells. The composition targets CAR-T cells to the vicinity of cancer cells, whereby upon activation, the CAR-T cells can effectuate cancer cell death.

Abstract: Provided herein are pH-responsive nanovaccines (NVs) that stimulate the immune system. The NVs comprise nano- or micro-particles to which CDN-modified i-motif DNA is attached. When endocytosed within a subject to whom they are delivered, the change in pH to an acidic environment cause the CDNs to be released from the NVs. The CDNs are STING (stimulator of interferon genes) agonists and after their release, they bind to and activate STING, a critical step in stimulating the immune system. The NVs are used e.g. for cancer immunotherapy, to treat viral infections and/or as vaccine adjuvants.

Abstract: Prophylactic compositions for inhibiting or reducing HIV infection and methods of their use are provided. One embodiment provides an antibody or an antigen binding fragment thereof that specifically binds to an HIV protein, for example gp120, and Cinhibits or reduces the ability of the HIV vims to infect human cells. One embodiment provides a PGT121 antibody or antigen binding fragment thereof modified to contain a GPI membrane anchor, wherein the antibody specifically binds to an HIV protein. In some embodiments the GPI membrane anchor is in the heavy chain of the antibody or antigen fragment thereof. In some aspects the antibody or antigen binding fragment specifically to gp120 or gp41.

Abstract: The present disclosure relates to methods and compositions for the localized expression of IL-12, preferably in combination with an RIG-I agonist, for activating a memory T cell response to a cancer antigen. In embodiments, the method is effective for treating metastatic disease.

Abstract: Provided is a dual recombinant viral vector system for expressing, in a cell, a polypeptide molecule which is composed of two different peptide chains and has an antigen binding activity, wherein the first chain is expressed using a first viral vector, the second chain is expressed using a second viral vector, and the first and second chains can be assembled, after being expressed in a cell, into the polypeptide molecule which has an antigen binding activity. Further provided are a dual plasmid system for the production of the dual recombinant viral vector system, a host cell containing the dual recombinant viral vector system, a pharmaceutical composition, and the use of and the method for delivering the polypeptide molecule to a subject by using the dual recombinant viral vector system.

Abstract: Synthetic nucleic acids encoding mini and microdystrophin genes comprising the membrane binding motifs or domains of the R10-R11-R12 region are provided. Also provided are vectors, host cells, and related methods of using the same to treat a subject suffering from Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD) or X-linked dilated cardiomyopathy (XLDC), or for ameliorating one or more adverse effects of DMD, BMD, or XLDC. Also provided are a fusion protein comprising a nNOS binding domain of dystrophin R16-R17 that is operably linked to a syntrophin PDZ domain and synthetic nucleic acids comprising the same that can be used to treat subjects with diseases characterized by loss of sarcolemmal neuronal nitric oxide synthase (nNOS) activity.

Abstract: The disclosure features compositions and methods for treating subjects 25 years of age or older having biallelic mutations in otoferlin (OTOF) by way of OTOF gene therapy. The disclosure provides a variety of compositions that include a first nucleic acid vector that contains a polynucleotide encoding an N-terminal portion of an OTOF protein and a second nucleic acid vector that contains a polynucleotide encoding a C-terminal portion of an OTOF protein. These vectors can be used to treat hearing loss or auditory neuropathy in a subject having biallelic OTOF mutations.

Abstract: The present invention provides compositions and methods for treating a neuromuscular disorder. In certain embodiments, the invention provides compositions and methods for assessing weaning readiness and continuation of weaning off of a mechanical ventilator in a subject with X-linked myotubular myopathy (XLMTM).

Abstract: The present disclosure provides, among other things, vectors for expression of ENPP1 or ENPP3 in vivo and methods for the treatment of diseases of calcification and ossification in a subject.

Abstract: The present invention provides compositions and methods useful for treating disorders amenable to therapy via introduction of multigenic expression vectors. More particularly, the invention provides vectors and polynucleotides encoding polypeptides for treatment of cardiac disorders wherein said polypeptides may comprise a cytokine, a chemokine, and/or an angiogenic polypeptide, or functional derivatives thereof. Also provided, as compositions of the invention, are linkers useful for connecting and expressing functional (biologically active) polypeptides from single, multigenic-expression constructs.

Abstract: The present invention relates to an eye-drop composition comprising 2-amino-9-[[(1S,2R)-1,2-bis(hydroxymethyl)cyclopropyl]methyl]-1,9-dihydro-6H-Purin-6-one, and the use thereof for the diagnosis and treatment of herpetic eye infections in companion animals.

Abstract: The present invention relates to nanoscale polymer dots (Pdots) that include strongly light absorbing semiconducting polymer nanoparticles doped with near-IR emitting dyes. The polymer functions as an antenna and transfers the excitation energy to the doped near-IR emitting dye molecules, which function as the emitting entity. The resulting Pdots feature very bright near-IR emission with emission wavelength tunability, high water solubility, and stability in biological solutions.

Abstract: The present subject matter provides compounds, compositions, and methods for identifying, monitoring, treating, and removing diseased tissue. Compounds, compositions, and methods for identifying, monitoring, and detecting circulating fluids such as blood are also provided.

Abstract: The present disclosure provides activatable and detectable membrane-interacting peptides that, following activation, can interact with phospholipid bilayers, such as cell membranes. The present disclosure also provides methods of use of such compounds. The compounds of the present disclosure are of the general structure X1a-A-X2-Z-X1b, where A is a membrane-interacting peptide region having a plurality of nonpolar hydrophobic amino acid residues that, following separation from portions Z, is capable of interaction with a phospholipid bilayer; Z is an inhibitory peptide region that can inhibit the activity of portion A; X2 is a cleavable linker that can be cleaved to release cleavage products from the compound; and X1a and X1b are optionally-present chemical handles that facilitate conjugation of various cargo moieties to the compound. Prior to cleavage of the composition at X2, the composition acts as a promolecule that does not associate with cellular membranes to a significant or detectable level.

Abstract: A liposomal nanocarrier delivery system for targeting an active CD44 molecule, preparation method therefor, and uses therof. The surface of the liposome is partially modified by a targeting ligand, wherein the targeting ligand is a ligand that can be specifically combined with the active CD44 molecule. The liposomal nanocarrier delivery system can be used for diagnosing, preventing, and treating vulnerable plaque or diseases related to vulnerable plaque.

Abstract: The invention provides nanodroplets labeled with targeting ligands that are useful in the detection and treatment of vascular thromboses (e.g., fibrin clots) and vascular plaques, or related diseases and conditions, as well as methods of preparation and use thereof.

Abstract: Provided herein are compounds useful for binding to one or more histone deacetylase enzymes (HDACs). The present application further provides radiolabeled compounds useful as a radiotracer for position emission tomography imaging of HDAC. Methods for prepared unlabeled and labeled compounds, diagnostic methods, and methods of treating diseases associated HDAC are also provided.

Abstract: The present invention relates to ligands of Fibroblast Activation Protein (FAP) for the active delivery of various payloads (e.g. cytotoxic drugs, radionuclides, fluorophores, proteins and immunomodulators) at the site of disease. In particular, the present invention relates to the development of bivalent FAP ligands for targeting applications, in particular diagnostic methods and/or methods for therapy or surgery in relation to a disease or disorder, such as cancer, inflammation or another disease characterized by overexpression of FAP.

Abstract: The invention relates to a kit for targeting of a diagnostic or therapeutic agent to a target site comprising: (a) a first conjugate comprising (i) a targeting moiety capable of binding selectively to the target site; and (ii) a first hybridization probe moiety comprising a PNA oligomer; and (b) a second conjugate comprising (i) a second hybridization probe moiety comprising a complementary PNA oligomer; and (ii) a diagnostic agent or a therapeutic agent moiety; wherein the length of the complementary PNA oligomer in the second hybridization probe moiety is not more than 14 bases. The invention further relates to methods for delivering a diagnostic or therapeutic agent to a target site in mammals, as well as methods for the diagnosis or treatment of medical conditions, such as e.g. cancer, in mammals.

Abstract: Certain embodiments are directed to methods for loading a liposome-containing alginate microsphere with an agent when the liposome-containing microsphere has been formed prior to loading of the liposome.

Abstract: A navel cleaning device features a housing, a capsule containing a cleaning agent, and a dispensing mechanism that can be actuated to release the cleaning agent. The device may include a base circumscribing an aperture of the housing, and may include an applicator adjacent to or within the aperture. Upon placing the navel cleaning device on the abdomen of a user, actuation of the dispensing mechanism releases cleaning agent into the applicator for delivery to the navel. After the cleaning process, a clinician or user may then remove any liquid or residue from the navel. The navel cleaning device provides a means to cleanse the navel prior to surgical procedures performed therethrough, leading to a reduction in the overall time and expense of the operation.

Abstract: The invention is a combination of direct air and surface disinfection and air purification all in one device (three-in-one). Disinfecting spaces can be a timely task, but with this invention surfaces and air can be disinfected in seconds, when direct disinfection is used. With humans or animals present, the device can be used in an indirect disinfection configuration to continue minimizing potential pathogens in the air. The invention uses UVC (germicidal) lamps, a proven technology for disinfecting pathogens. When the top is off direct air and surface disinfection occurs. In this configuration, the design has been optimized by using a unique open cage design, so the light will transmit from all directions with minimal absorption to components on the device. This in combination with the lamp pattern results in a very precise UVC light emission, required for adequate, consistent disinfection of the surfaces and the air.

Abstract: Disclosed is an in-vehicle sterilization system. The system includes a sterilizer that includes one or more ultraviolet (UV) light-emitting diodes (LEDs). The system also includes processors that determine a time point at which the sterilizer is to be operated, and control operation of the sterilizer according to a result of the determination.

Abstract: The embodiments herein relate to a device for disinfection of stethoscope headpiece using dual means working simultaneously. The device of the present invention provides a two-advantage system of simultaneously using photo and chemical disinfection methods. According to an embodiment herein, the device comprises a disinfection chamber equipped with photo-disinfection means having multiple ultraviolet-C LED radiation lamps and chemical disinfection means having chemical spray nozzles. The device of the present invention has an additional functionality of disinfecting stethoscope headpiece using chemical liquid spray making the disinfection process more efficient and a reduced disinfection time.

Abstract: A sterilization device includes a housing; a sterilization unit which emits germicidal light for sterilization of at least one target area to be sterilized; and a drive unit which moves at least a part of the sterilization unit between the outside and inside of the housing through an opening provided in the housing.

Abstract: An apparatus for sanitizing a point-of-contact surface may include a housing configured to be affixed about at least a portion of said point of contact. The housing may have an interior in or through which the point of contact may be accessed and an anterior opening for access to the interior. The apparatus may further include one or more sources of a sanitizing agent, such as germicidal light, configured to direct the sanitizing agent toward a location where at least a portion of the point-of-contact surface may be disposed. One or more of an anterior dome, an inner surface, and a posterior surface may also be configured to reflect the sanitizing agent toward the location where at least a portion of the point-of-contact surface may be disposed.

Abstract: An apparatus for inactivating bacteria or viruses in a space, the apparatus includes a light source unit that emits ultraviolet light having a peak wavelength within a wavelength range of 190 nm or more and less than 240 nm, an irradiation region changing mechanism that changes an irradiation direction of the ultraviolet light of the light source unit, and a driving unit that drives the irradiation region changing mechanism to change the irradiation direction of the ultraviolet light of the light source unit.

Abstract: An apparatus includes a first production line configured to generate aqueous ozone with a first ozone concentration. The apparatus also includes an additional production line configured to generate aqueous ozone with an additional ozone concentration. The first production line and the additional production line include a flow switch, where fluid is configured to flow through the flow switch. The first production line and the additional production line include an ozone generator, where the ozone generator is configured to generate ozone when the fluid flows through the flow switch. The first production line and the additional production line include a fitting coupled to the flow switch and the ozone generator, where the fitting is configured to combine the generated ozone and the fluid to generate the aqueous ozone. The first production line is configured to generate aqueous ozone independently from the additional production line.

Abstract: An apparatus for delivering a volatile material in a continuous manner is disclosed. The apparatus includes a delivery engine having a reservoir for containing a volatile material; a rupturable substrate secured to the reservoir; a rupture element positioned adjacent to the rupturable substrate; and a breathable membrane enclosing the reservoir, rupturable substrate and rupture element.

Abstract: To provide a scent dispensing device capable of appropriately and quickly removing an unnecessary scent component remaining in the device after dispensing a scent. A scent dispensing device 100 includes: a scenting portion 101 that emits a scent-containing air flow containing a scent; a space portion 102 that causes the scent-containing air flow emitted from the scenting portion 101 to pass or remain; a releasing portion 103 that releases the scent-containing air flow having passed through the space portion 102 to a user M; an exhaust portion 104 that exhausts the scent-containing air flow remaining in the space portion 102 to the outside; and a scent component trap portion 105 that traps a volatile component in the scent-containing air flow to be exhausted by the exhaust portion 104.

Abstract: The present disclosure provides for and includes improved devices and methods for the production of Purified Hydrogen Peroxide Gas (PHPG) that is substantially non-hydrated and substantially free of ozone.

Abstract: A sterilizing panel lamp, including at least one housing, at least one frame body, at least one sterilization assembly, and at least one fan, where the frame body is arranged at the bottom peripheral side of the housing, the frame body encloses a mounting surface, at least an inlet grille, a lighting assembly, and an outlet grille are arranged along the mounting surface in a transverse or longitudinal direction, the inlet grille is detachably arranged between the frame body and lighting assembly, and the housing, frame body, inlet grille, lighting assembly and outlet grille enclose to form an air flow passage; the sterilization assembly is provided in the air flow passage; the fan is provided in the air flow passage, and the fan rotates to accelerate the speed at which air enters from the inlet grille and blows out of the outlet grille through the air flow passage.

Abstract: Provided is a lighting device with an inactivation function, the lighting device allowing the addition of an inactivation function while being equal to conventional lighting devices in device size. The lighting device with the inactivation function includes: a UVC light source to emit ultraviolet light having a peak wavelength in a wavelength range from 200 nm to 230 nm; an LED light source to emit visible light; a single unit of an AC/DC converter to convert an AC voltage derived from an external power source into a DC voltage and output the DC voltage; a UVC light source-specific circuit part to convert the DC voltage output from the AC/DC converter into a voltage for lighting the UVC light source; and an LED light source-specific circuit part to convert the DC voltage output from the AC/DC converter into a current for lighting the LED light source.